EIF4A3 Antibody

What is EIF4A3 and what is its primary function in cellular processes?

EIF4A3 (eukaryotic translation initiation factor 4A, isoform 3) is a member of the DEAD box RNA helicase family with a molecular weight of approximately 47 kDa. Unlike its paralogs eIF4A1 and eIF4A2 which function in translation initiation, eIF4A3 serves as a core component of the exon junction complex (EJC) . The EJC assembles near exon-exon junctions of mRNAs as a result of splicing and participates in various post-splicing events, including mRNA export, cytoplasmic localization, and nonsense-mediated decay (NMD) . EIF4A3 functions as an ATP-dependent RNA clamp that serves as a nucleation center to recruit other EJC components, and its depletion leads to defects in nonsense-mediated decay mechanisms .

How should I select an appropriate EIF4A3 antibody for my research application?

When selecting an EIF4A3 antibody, consider the following criteria based on your experimental needs:

• Application compatibility: Determine whether the antibody has been validated for your specific application (WB, IP, IHC, IF/ICC, etc.) with demonstrated positive results.

• Species reactivity: Ensure the antibody recognizes EIF4A3 in your species of interest. Available antibodies show reactivity with human, mouse, and rat samples .

• Clonality: Choose between polyclonal antibodies (which recognize multiple epitopes) or monoclonal antibodies (which target a single epitope).

• Publication record: Check if the antibody has been cited in publications for your specific application.

For instance, if planning Western blot experiments with human and mouse samples, both 17504-1-AP and 10463-1-AP antibodies would be suitable, though they have different recommended dilution ranges (1:1000-1:4000 and 1:500-1:2000, respectively) .

What are the recommended sample types for detecting EIF4A3?

EIF4A3 can be successfully detected in various sample types, depending on the application and antibody used. Based on validation data:

When working with tissue samples, note that antigen retrieval conditions may affect detection efficiency, with Tris-EDTA buffer pH 9.0 being suggested for optimal results, though citrate buffer pH 6.0 may serve as an alternative .

What are the optimal dilution conditions for EIF4A3 antibodies in different applications?

Proper antibody dilution is critical for obtaining specific signal with minimal background. Based on validated data, the following dilutions are recommended:

It is important to note that these ranges serve as starting points, and optimization for your specific experimental system is strongly recommended . When optimizing:

• Begin with the middle of the recommended range

• Test multiple dilutions in parallel

• Consider blocking conditions and incubation times as variables

• Use positive controls to confirm appropriate detection

How should I design experiments to investigate EIF4A3 interaction with other proteins?

To investigate EIF4A3 interactions with other proteins, multiple complementary approaches should be employed:

• Co-immunoprecipitation (Co-IP): Use anti-EIF4A3 antibodies for IP followed by Western blotting for potential interacting partners. RNase A treatment should be included to distinguish RNA-dependent and direct protein-protein interactions, as demonstrated in EIF4A3-eIF3g interaction studies .

• GST pull-down assays: Utilize GST-tagged EIF4A3 or its potential binding partners for in vitro interaction studies. For example, the interaction between EIF4A3 and eIF3g was confirmed using both recombinant proteins in GST pull-down assays .

• Proximity Ligation Assay (PLA): This technique provides high specificity and enables precise detection of protein-protein interactions within cells, allowing visualization of interaction sites. PLA successfully detected EIF4A3 interactions with eIF3 components in both nucleus and cytoplasm .

• Deletion mapping: To identify interaction domains, construct deletion variants of EIF4A3 or its binding partners. For example, the region corresponding to amino acid residues 151-186 of eIF3g was identified as essential for binding to EIF4A3 through deletion analysis .

• Far Western blotting: This approach uses purified recombinant proteins to detect direct interactions, as demonstrated with His-eIF4A3 and purified eIF3 complex .

What controls should be included when using EIF4A3 antibodies in experimental workflows?

Proper controls are essential for interpreting results from experiments utilizing EIF4A3 antibodies:

• Positive control: Include lysates or samples known to express EIF4A3 (e.g., HeLa cells, HEK-293 cells, or mouse heart tissue) to verify antibody functionality .

• Negative control: Consider:

  • Primary antibody omission to assess secondary antibody specificity

  • Isotype control (rabbit IgG) to evaluate non-specific binding

  • RNase A treatment in interaction studies to determine RNA-dependency

• siRNA knockdown control: Downregulation of EIF4A3 by siRNA should substantially reduce antibody signal, confirming specificity .

• Loading controls: Include appropriate loading controls for Western blot (e.g., GAPDH, β-actin) to normalize protein levels.

• Subcellular localization controls: When performing immunofluorescence, include markers for relevant cellular compartments, as EIF4A3 has been detected in both nuclear and cytoplasmic locations .

How can I investigate the role of EIF4A3 in nonsense-mediated decay (NMD) pathways?

Investigating EIF4A3's role in NMD requires specialized experimental approaches:

• NMD reporter assays: Utilize reporter constructs containing premature termination codons (PTCs) to measure NMD efficiency. The effect of EIF4A3 modulation (knockdown, overexpression, or inhibition) on reporter expression can be quantified.

• EIF4A3 variant analysis: Express EIF4A3 variants with specific mutations affecting ATP binding/hydrolysis (e.g., E188Q), phosphorylation state (T163A, T163D), or interaction with other EJC components (D154K/Y155A, D401K/E402R) to dissect functional domains .

• RNA tethering assays: Tether EIF4A3 to reporter mRNAs using λN-BoxB or MS2-based systems to study its direct effects on RNA fate. As demonstrated in research, tethering experiments with various EIF4A3 variants revealed differential effects on translation activity .

• RNA immunoprecipitation (RIP): Use RIP assays to identify endogenous RNA targets of EIF4A3, as evidenced by multiple publications utilizing this technique with EIF4A3 antibodies .

• EIF4A3 inhibitor studies: Employ selective EIF4A3 inhibitors to acutely block function and observe effects on NMD. Inhibitor selectivity can be confirmed through comparison of eutomers and distomers, with the former showing significant NMD inhibition while the latter do not .

What methods can be used to distinguish EIF4A3 from other EIF4A family members in experimental systems?

Distinguishing EIF4A3 from its paralogs EIF4A1 and EIF4A2 is crucial due to their structural similarity but distinct functions:

• Antibody specificity: Ensure antibodies are validated for specificity against EIF4A3 without cross-reactivity to EIF4A1/2. Western blots should show a single band at the expected molecular weight (47 kDa) .

• Subcellular localization: While EIF4A1/2 are predominantly cytoplasmic, EIF4A3 shows both nuclear and cytoplasmic distribution. Immunofluorescence with specific antibodies can help distinguish their localization patterns .

• Functional assays: EIF4A3 depletion primarily affects NMD and splicing, while EIF4A1/2 depletion impacts general translation. Design assays that specifically measure these distinct functions.

• Co-IP partners: EIF4A3 uniquely associates with EJC components (MAGOH, Y14, MLN51), while EIF4A1/2 interact with eIF4G and eIF4E. Co-IP experiments can identify these distinct interaction partners .

• Selective inhibitors: Utilize compounds that selectively inhibit EIF4A3 over other family members. Specificity can be confirmed through comparative activity assays .

How can I investigate EIF4A3's role in translation regulation independent of its EJC function?

Recent research has revealed EIF4A3 functions in translation that may be independent of its canonical EJC role:

• Polysome profiling: Analyze EIF4A3 association with polysomes to determine its involvement in actively translating ribosomes, which would differ from its known nuclear EJC function.

• Translation reporter assays: Utilize bicistronic reporters with internal ribosome entry sites (IRES) to assess cap-independent translation mechanisms potentially regulated by EIF4A3.

• EIF4A3-eIF3 interaction studies: Investigate the direct interaction between EIF4A3 and translation initiation factor eIF3, particularly eIF3g. The region corresponding to amino acids 151-186 of eIF3g is essential for EIF4A3 binding and can be manipulated to study functional consequences .

• EIF4A3 variant expression: Express EIF4A3 variants like T163A (which stably associates with EJC components) and T163D (which cannot bind EJC components) to separate EJC-dependent and independent functions .

• RNA tethering with EJC-binding deficient mutants: Utilize EIF4A3 mutants that cannot incorporate into the EJC (D154K/Y155A or D401K/E402R) to dissect EJC-independent roles in translation .

What are common issues in EIF4A3 detection by Western blot and how can they be resolved?

Several technical challenges may arise when detecting EIF4A3 by Western blot:

• Weak or no signal:

  • Increase antibody concentration within recommended range (try 1:1000 for 17504-1-AP or 1:500 for 10463-1-AP)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Increase protein loading (20-40 μg total protein)

  • Verify EIF4A3 expression in selected sample type

  • Check transfer efficiency with reversible protein stain

• High background:

  • Increase blocking duration (1-2 hours)

  • Use higher dilution of antibody (up to 1:4000 for 17504-1-AP)

  • Add 0.1-0.5% Tween-20 to washing and antibody dilution buffers

  • Reduce secondary antibody concentration

• Multiple bands:

  • Increase stringency of blocking and washing

  • Confirm sample integrity (add protease inhibitors during lysis)

  • Validate antibody specificity via knockdown controls

  • Consider post-translational modifications or splice variants

• Inconsistent results between samples:

  • Standardize protein extraction method

  • Ensure equal protein loading with appropriate controls

  • Maintain consistent transfer conditions

  • Use freshly prepared samples when possible

How should I optimize immunoprecipitation protocols for EIF4A3 and its interaction partners?

Optimizing immunoprecipitation of EIF4A3 requires consideration of several factors:

• Antibody amount: For optimal IP, use 0.5-4.0 μg antibody per 1.0-3.0 mg of total protein lysate . Start with a mid-range amount and adjust based on results.

• Lysis conditions:

  • Use non-denaturing lysis buffers (e.g., RIPA or NP-40 based)

  • Include protease and phosphatase inhibitors

  • Consider whether to maintain or disrupt RNA-dependent interactions by including or omitting RNase A treatment

• Binding conditions:

  • Pre-clear lysates with protein A/G beads

  • Incubate antibody with lysate overnight at 4°C with gentle rotation

  • For weak interactions, consider chemical crosslinking

• Washing stringency:

  • For strong interactions, use more stringent washing (higher salt concentration)

  • For weaker interactions, use lower stringency washes

  • Always include a final low-salt wash to remove salt before elution

• Detection of interaction partners:

  • For known interactions (e.g., with eIF3g), use antibodies against specific partners

  • For discovering novel interactions, consider mass spectrometry analysis of IP eluates

• Validation of interactions:

  • Perform reciprocal IPs (IP potential partner, blot for EIF4A3)

  • Use multiple detection methods (IP, GST pull-down, PLA) to confirm interactions

What factors affect EIF4A3 detection in immunohistochemistry and immunofluorescence applications?

Several factors can influence the success of EIF4A3 detection in IHC and IF applications:

• Fixation method:

  • For IHC, formalin-fixed paraffin-embedded tissues are commonly used

  • For IF, 4% paraformaldehyde fixation for 10-15 minutes is typically sufficient

  • Over-fixation can mask epitopes and reduce antibody binding

• Antigen retrieval:

  • For EIF4A3 detection, TE buffer pH 9.0 is recommended for optimal antigen retrieval

  • Alternative methods include citrate buffer pH 6.0

  • Heat-induced epitope retrieval (pressure cooker or microwave) is preferable to enzymatic methods

• Antibody concentration:

  • For IHC, use 1:20-1:200 dilution of 17504-1-AP antibody

  • For IF, use 1:10-1:100 dilution of 17504-1-AP antibody

  • Always titrate antibodies to determine optimal concentration for your specific sample

• Detection systems:

  • For IHC, consider polymer-based detection systems for enhanced sensitivity

  • For IF, select secondary antibodies with appropriate fluorophores based on microscope capabilities

• Controls:

  • Include positive control tissues with known EIF4A3 expression (e.g., human kidney, brain, heart, lung tissues)

  • Include negative controls (primary antibody omission, isotype control)

  • Consider siRNA knockdown in cell lines as specificity controls

How can EIF4A3 inhibitors be used as research tools to study its function?

Recent development of selective EIF4A3 inhibitors provides valuable tools for studying its function:

• Acute vs. chronic inhibition: Unlike genetic approaches (siRNA, CRISPR) which cause prolonged depletion, small molecule inhibitors allow temporal control over EIF4A3 inactivation, enabling studies of immediate consequences vs. adaptive responses.

• Mechanistic studies: EIF4A3 inhibitors can be used to dissect which functions depend on its ATPase/helicase activity. For instance, compounds that interfere with ATP binding can reveal ATP-dependent vs. ATP-independent roles .

• Domain-specific inhibition: Various inhibitors may target different functional domains of EIF4A3, allowing selective disruption of specific interactions or activities:

  • ATP binding/hydrolysis inhibitors

  • RNA binding inhibitors

  • Protein-protein interaction inhibitors

• Validating inhibitor specificity: Comparing effects of eutomers (active stereoisomers) with distomers (inactive stereoisomers) can confirm target specificity, as demonstrated in NMD inhibition studies .

• Combination approaches: Using inhibitors alongside mutation or depletion approaches can provide complementary insights. For example, inhibitors can be tested in cells expressing EIF4A3 variants to understand resistance mechanisms or synergistic effects.

What are the current methodological approaches to study EIF4A3's role in RNA splicing and processing?

Investigating EIF4A3's function in RNA processing requires specialized techniques:

• Transcriptome-wide splicing analysis:

  • RNA-seq following EIF4A3 depletion or inhibition

  • Analysis of alternative splicing events using computational tools (e.g., rMATS, VAST-TOOLS)

  • Validation of splicing changes by RT-PCR

• Direct RNA binding studies:

  • RNA immunoprecipitation (RIP) using EIF4A3 antibodies to identify bound transcripts

  • Cross-linking immunoprecipitation (CLIP) for higher resolution mapping of binding sites

  • In vitro RNA binding assays with purified recombinant EIF4A3

• EJC assembly and dynamics:

  • IP of EIF4A3 under various conditions to assess EJC component association

  • Use of EIF4A3 variants with altered binding properties (T163A, T163D, D154K/Y155A, D401K/E402R, E188Q) to dissect complex assembly requirements

  • Fluorescence recovery after photobleaching (FRAP) to study EJC component dynamics

• Functional reporter assays:

  • Minigene splicing reporters to assess effects on specific splicing events

  • RNA tethering assays to study position-dependent effects of EIF4A3 on RNA processing

  • Translation reporters to evaluate downstream consequences of altered splicing/EJC assembly

How can I investigate the potential role of EIF4A3 in disease mechanisms and therapeutic applications?

EIF4A3's involvement in fundamental RNA processing makes it potentially relevant to various disease states:

• Expression analysis in disease states:

  • Use validated antibodies (17504-1-AP, 10463-1-AP) to assess EIF4A3 protein levels in disease vs. normal tissues by IHC, WB

  • Compare expression in paired normal/diseased samples to identify dysregulation

• Genetic screening:

  • Analyze EIF4A3 mutations or expression changes in patient samples

  • Use CRISPR-Cas9 screening to identify synthetic lethal interactions with EIF4A3 in disease models

• Disease-relevant NMD targets:

  • Identify disease-relevant transcripts regulated by NMD and EIF4A3

  • Investigate whether EIF4A3 modulation affects levels of these transcripts

• Therapeutic targeting:

  • Use selective EIF4A3 inhibitors to evaluate effects on disease phenotypes

  • Compare effectiveness and specificity of different chemical scaffolds

  • Assess effects in relevant disease models (cell lines, patient-derived samples, animal models)

• Biomarker potential:

  • Evaluate correlation between EIF4A3 expression/activity and disease progression

  • Determine whether EIF4A3 status predicts response to specific therapies